Ripretinib Alternatives Compared
| Ripretinib | Gleevec (imatinib) | Imatinib |
|
|---|
| Ripretinib | Gleevec (imatinib) | Imatinib |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Gastrointestinal Stromal Tumor. Ripretinib may also be used for purposes not listed in this medication guide. |
Prescription only
Gleevec is an oral tyrosine kinase inhibitor that may be used to treat Ph+CML, Ph+ALL, and some other conditions. It may cause fluid retention, nausea, pain, headache, or blood abnormalities and... View more |
Prescription only
Prescribed for Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Dermatofibrosarcoma Protuberans, Chronic Eosinophilic Leukemia, Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome... View more |
Related suggestions Gastrointestinal Stromal Tumor
|
|||||||||||||||
| More about Ripretinib | More about Gleevec (imatinib) | More about Imatinib | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Ripretinib has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Gleevec has an average rating of 8.6 out of 10 from a total of 37 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 5% reported a negative effect. |
Imatinib has an average rating of 8.8 out of 10 from a total of 47 ratings on Drugs.com. 87% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Ripretinib side effects |
View all Gleevec side effects |
View all Imatinib side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Gleevec prices |
View all Imatinib prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Qinlock | Other imatinib brands include: Imkeldi | Gleevec, Imkeldi | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
17.8 hours |
40 hours |
40 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 339 drugs are known to interact with Ripretinib:
|
A total of 755 drugs are known to interact with Gleevec:
|
A total of 755 drugs are known to interact with Imatinib:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
May 15, 2020 |
May 10, 2001 |
April 18, 2003 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.